Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma

NCT00461786 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00461786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00461786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
May 31, 2008
Enrollment
51 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, peritoneal cancer